Developer docs
API playgroundTry for free, no card

Search company profiles

Treovir

Full company profile

uuid000ebvj

Namestring
Treovir
Legal namestring
Treovir LLC
Websiteurl
treovir.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Treovir is a clinical-stage biopharmaceutical company founded in 2019 to develop and commercialize G207, a modified oncolytic herpes simplex virus type 1 (HSV-1) immunotherapy, for pediatric brain tumors. The company targets children with recurrent high-grade glioma (HGG) — including glioblastoma and medulloblastoma — an addressable population of approximately 3,900 children diagnosed with primary brain tumors each year in the US, an indication with zero FDA-approved therapies. The firm is headquartered in Bala Cynwyd, Pennsylvania, operates with 1-10 employees, and is privately held with no disclosed institutional venture capital backing.

G207 is engineered to selectively infect and kill tumor cells while sparing healthy tissue and is administered as a single intratumoral infusion. The mechanism combines direct oncolysis with a T-cell-mediated inflammatory response that converts immunologically "cold" tumors into "hot" ones, recruiting the patient's own immune system to attack residual disease. Treovir has dosed more than 40 adult and nearly 20 pediatric brain tumor patients across three Phase 1 trials, with Phase 1 pediatric data published in the New England Journal of Medicine (April 2021) showing overall survival of 12.2 months versus 5.6 months for historical controls and no serious adverse events. A Phase 2 study in 30 pediatric patients with recurrent HGG was launched in 2024 at MD Anderson Cancer Center and Memorial Sloan Kettering to support registration, alongside a Phase 1 combination study with radiation in cerebellar tumors.

Treovir is pre-revenue. The economic model is contingent on FDA and EMA approval of G207, at which point revenue would be generated through commercial sales of the therapy administered in hospital/clinical settings. G207 has received FDA Fast Track designation, FDA Orphan Product designation for glioma, medulloblastoma, and pediatric neuroectodermal tumors (PNET), and EMA Orphan designation for glioma. The company operates an Expanded Access Program for patients outside clinical trials and runs trials in partnership with MD Anderson, Memorial Sloan Kettering, Children's of Alabama, St. Louis Children's Hospital, the Pediatric Brain Tumor Consortium, NIH, and UAB Medicine, where scientific co-founder G. Yancey Gillespie (CSO) is Professor Emeritus of Neurosurgery and where James Markert chairs Neurosurgery.

Short descriptiontext

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy delivered as a single intratumoral infusion to treat pediatric patients with recurrent high-grade glioma, an indication with no FDA-approved therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncolytic virus therapy, pediatric brain tumors, immunotherapy biotech, HSV-based therapeutics, clinical-stage biopharmaceuticals
Industry1 code
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncolytic Virus Immunotherapy
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biotech Revenue (Future)
TypeOne Time License
Description

Treovir is a pre-revenue clinical-stage company. If G207 receives FDA and EMA approval, revenue would be generated through commercial sales of the therapy for pediatric brain tumors. No specific pricing, reimbursement, or commercial launch timeline has been disclosed.

treovir.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 (herpes simplex virus type 1) immunotherapy engineered to selectively infect and kill tumor cells while leaving healthy cells unharmed. G207 is administered as a single infusion directly into the brain tumor, causing direct tumor cell death and recruiting the patient's own immune system (T-cell response) to fight the cancer. The company is pursuing FDA approval of G207 for pediatric high-grade glioma, an indication with no currently approved therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Overall survival improved to 12.2 months vs 5.6 months historical control in Phase 1 pediatric study
+2 more records
Product overview1 text field

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy for pediatric brain tumors. The core product G207 is a targeted oncolytic virus therapy administered as a single infusion directly into the tumor. The company has completed Phase 1 studies demonstrating safety and improved survival, and launched a Phase 2 study in 2024 to support FDA registration. If successful, G207 would become the first-ever approved therapy for pediatric glioma.

Product and service4 records
1G207 Oncolytic Immunotherapy
CategoryOncolytic Virus Therapy
Description

G207 is a modified oncolytic HSV-1 immunotherapy that selectively infects and kills tumor cells while sparing healthy cells. Administered as a single direct intratumoral infusion, it triggers tumor cell death and recruits T-cell immune responses to convert immunologically 'cold' tumors 'hot'. It is being developed for pediatric brain tumors including recurrent high-grade glioma and medulloblastoma, targeting an indication with no currently approved FDA therapies.

2Phase 2 Pediatric Glioma Clinical Trial (NCT04482933)
CategoryClinical Trial
Description

Active Phase 2 clinical trial of G207 in children with recurrent high-grade glioma, designed to support FDA market approval. Currently enrolling at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

3Phase 1 Pediatric HGG Clinical Trial (NCT02457845)
CategoryClinical Trial
Description

Completed Phase 1 clinical study of G207 in 12 pediatric patients with recurrent high-grade glioma, demonstrating improved overall survival versus historical controls with no serious adverse events. Results published in the New England Journal of Medicine (Friedman GK, April 2021).

4Phase 1 Cerebellar Tumor Clinical Trial (NCT03911388)
CategoryClinical Trial
Description

Phase 1 study of G207 in combination with 5Gy radiation in patients with recurrent medulloblastoma and other cerebellar tumors. Enrolling up to 15 patients at MD Anderson Cancer Center, Children's of Alabama, and St. Louis Children's Hospital.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MD Anderson Cancer Center is an enrolling site for both the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma and the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. MD Anderson is one of the world's most respected cancer treatment centers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Memorial Sloan Kettering Cancer Center is an enrolling site for the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma. Memorial Sloan Kettering is a leading pediatric oncology center.

3Children's of Alabama
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Children's of Alabama is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. The hospital has been involved in pediatric brain tumor research with G207.

treovir.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

St. Louis Children's Hospital is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PBTC is a collaborative research consortium focused on developing new treatments for pediatric brain tumors. The logo appears on Treovir's website indicating partnership in pediatric brain tumor clinical research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH supports pediatric brain tumor research and is listed as a partner on Treovir's website. The NIH logo appears indicating research funding or collaborative support for G207 development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UAB (University of Alabama at Birmingham) Medicine is a key research partner. Co-directed the Neuro Oncology Program and Brain Tumor SPORE in the UAB O'Neal Comprehensive Cancer Center. Founder Yancey Gillespie is Professor Emeritus of Neurosurgery at UAB.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Replimune is a clinical-stage biotech developing a proprietary platform of engineered oncolytic viruses (RP1, RP2, RP3) across multiple solid tumor indications. It is a direct modality peer with greater pipeline breadth and public-market funding that competes for the same oncolytic virus partnering and clinical site capacity.

TypeEmerging player
Description

Day One Biopharmaceuticals is a commercial-stage pediatric oncology company (tovorafenib/Day101) focused exclusively on childhood cancers. It is a peer in the pediatric oncology commercial and clinical-development niche that G207 would enter upon approval.

TypeDirect peer
Description

SillaJen developed Pexa-Vec (JX-594), an oncolytic vaccinia virus, in hepatocellular carcinoma and other solid tumors. It is a clinical-stage direct peer in the oncolytic virus modality with overlapping clinical-trial and regulatory dynamics.

4Oncorus
TypeDirect peer
Description

Oncorus developed intratumorally and intravenously administered oncolytic HSV-1 immunotherapies for cancer. It is a direct peer in the oncolytic HSV modality that Treovir is built on, with overlapping mechanistic and manufacturing considerations.

TypeDirect peer
Description

Genelux is developing Olvi-Vec, an oncolytic vaccinia virus, in solid tumors including lung and ovarian cancers. It is a direct modality peer in the clinical-stage oncolytic virus space, competing for investigator attention and partnership capital.

TypeDirect peer
Description

Vyriad is developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms for solid tumors. It is a direct peer in clinical-stage oncolytic virus development with similar regulatory and manufacturing challenges to Treovir.

TypeEmerging player
Description

Y-mAbs Therapeutics develops and commercializes antibody-based oncology therapies targeted at pediatric tumors, including Danyelza for neuroblastoma. It is comparable as a small, pediatric-cancer-focused biotech operating in the same regulatory and reimbursement environment.

TypeDirect peer
Description

DNAtrix is a clinical-stage oncolytic virus company developing DNX-2401 (tasadenoturev), an oncolytic adenovirus for brain tumors including glioblastoma. It is the most directly comparable peer because it targets the same brain tumor indication with the same oncolytic virus modality as Treovir.

TypeDirect peer
Description

Candel Therapeutics (formerly Advantagene) develops CAN-2409, an oncolytic adenovirus gene therapy, with programs in prostate cancer and high-grade glioma. It directly overlaps Treovir in intratumoral oncolytic virus delivery and brain-tumor indication.

TypeBroad incumbent
Description

Amgen developed and commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for melanoma. As the established commercial oncolytic virus player, it defines the regulatory and commercial template Treovir would face in bringing G207 to market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Treovir

Oncolytic Virus Immunotherapytreovir.com

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy delivered as a single intratumoral infusion to treat pediatric patients with recurrent high-grade glioma, an indication with no FDA-approved therapies.

What Treovir does

Treovir is a clinical-stage biopharmaceutical company founded in 2019 to develop and commercialize G207, a modified oncolytic herpes simplex virus type 1 (HSV-1) immunotherapy, for pediatric brain tumors. The company targets children with recurrent high-grade glioma (HGG) — including glioblastoma and medulloblastoma — an addressable population of approximately 3,900 children diagnosed with primary brain tumors each year in the US, an indication with zero FDA-approved therapies. The firm is headquartered in Bala Cynwyd, Pennsylvania, operates with 1-10 employees, and is privately held with no disclosed institutional venture capital backing.

G207 is engineered to selectively infect and kill tumor cells while sparing healthy tissue and is administered as a single intratumoral infusion. The mechanism combines direct oncolysis with a T-cell-mediated inflammatory response that converts immunologically "cold" tumors into "hot" ones, recruiting the patient's own immune system to attack residual disease. Treovir has dosed more than 40 adult and nearly 20 pediatric brain tumor patients across three Phase 1 trials, with Phase 1 pediatric data published in the New England Journal of Medicine (April 2021) showing overall survival of 12.2 months versus 5.6 months for historical controls and no serious adverse events. A Phase 2 study in 30 pediatric patients with recurrent HGG was launched in 2024 at MD Anderson Cancer Center and Memorial Sloan Kettering to support registration, alongside a Phase 1 combination study with radiation in cerebellar tumors.

Treovir is pre-revenue. The economic model is contingent on FDA and EMA approval of G207, at which point revenue would be generated through commercial sales of the therapy administered in hospital/clinical settings. G207 has received FDA Fast Track designation, FDA Orphan Product designation for glioma, medulloblastoma, and pediatric neuroectodermal tumors (PNET), and EMA Orphan designation for glioma. The company operates an Expanded Access Program for patients outside clinical trials and runs trials in partnership with MD Anderson, Memorial Sloan Kettering, Children's of Alabama, St. Louis Children's Hospital, the Pediatric Brain Tumor Consortium, NIH, and UAB Medicine, where scientific co-founder G. Yancey Gillespie (CSO) is Professor Emeritus of Neurosurgery and where James Markert chairs Neurosurgery.

Treovir firmographics

Firmographics
Name
Treovir
Legal name
Treovir LLC
Website
https://treovir.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy delivered as a single intratumoral infusion to treat pediatric patients with recurrent high-grade glioma, an indication with no FDA-approved therapies.
Ownership category
akta.pro rank

Treovir industry classification

Industry
Product category
Oncolytic Virus Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Oncolytic virus therapy
  • Pediatric brain tumors
  • Immunotherapy biotech
  • HSV-based therapeutics
  • Clinical-stage biopharmaceuticals

Where Treovir is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

Treovir business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical/Biotech Revenue (Future): Treovir is a pre-revenue clinical-stage company. If G207 receives FDA and EMA approval, revenue would be generated through commercial sales of the therapy for pediatric brain tumors. No specific pricing, reimbursement, or commercial launch timeline has been disclosed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Treovir product offering

Product offering

Core offering

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 (herpes simplex virus type 1) immunotherapy engineered to selectively infect and kill tumor cells while leaving healthy cells unharmed. G207 is administered as a single infusion directly into the brain tumor, causing direct tumor cell death and recruiting the patient's own immune system (T-cell response) to fight the cancer. The company is pursuing FDA approval of G207 for pediatric high-grade glioma, an indication with no currently approved therapies.

Product overview

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy for pediatric brain tumors. The core product G207 is a targeted oncolytic virus therapy administered as a single infusion directly into the tumor. The company has completed Phase 1 studies demonstrating safety and improved survival, and launched a Phase 2 study in 2024 to support FDA registration. If successful, G207 would become the first-ever approved therapy for pediatric glioma.

Differentiator

Problem solved

Functional benefit

Products and services

  • G207 Oncolytic Immunotherapy G207 is a modified oncolytic HSV-1 immunotherapy that selectively infects and kills tumor cells while sparing healthy cells. Administered as a single direct intratumoral infusion, it triggers tumor cell death and recruits T-cell immune responses to convert immunologically 'cold' tumors 'hot'. It is being developed for pediatric brain tumors including recurrent high-grade glioma and medulloblastoma, targeting an indication with no currently approved FDA therapies.
  • Phase 2 Pediatric Glioma Clinical Trial (NCT04482933) Active Phase 2 clinical trial of G207 in children with recurrent high-grade glioma, designed to support FDA market approval. Currently enrolling at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
  • Phase 1 Pediatric HGG Clinical Trial (NCT02457845) Completed Phase 1 clinical study of G207 in 12 pediatric patients with recurrent high-grade glioma, demonstrating improved overall survival versus historical controls with no serious adverse events. Results published in the New England Journal of Medicine (Friedman GK, April 2021).
  • Phase 1 Cerebellar Tumor Clinical Trial (NCT03911388) Phase 1 study of G207 in combination with 5Gy radiation in patients with recurrent medulloblastoma and other cerebellar tumors. Enrolling up to 15 patients at MD Anderson Cancer Center, Children's of Alabama, and St. Louis Children's Hospital.

Quantifiable outcome

  • Overall survival improved to 12.2 months vs 5.6 months historical control in Phase 1 pediatric study
  • +2 more outcomes

Companies that use Treovir

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Treovir technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Treovir partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center is an enrolling site for both the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma and the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. MD Anderson is one of the world's most respected cancer treatment centers.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerMemorial Sloan Kettering Cancer Center is an enrolling site for the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma. Memorial Sloan Kettering is a leading pediatric oncology center.
  • Children's of AlabamacoreStrategic or Co-development PartnerChildren's of Alabama is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. The hospital has been involved in pediatric brain tumor research with G207.
  • St. Louis Children's HospitalcoreStrategic or Co-development PartnerSt. Louis Children's Hospital is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors.
  • Pediatric Brain Tumor Consortium (PBTC)coreStrategic or Co-development PartnerPBTC is a collaborative research consortium focused on developing new treatments for pediatric brain tumors. The logo appears on Treovir's website indicating partnership in pediatric brain tumor clinical research.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH supports pediatric brain tumor research and is listed as a partner on Treovir's website. The NIH logo appears indicating research funding or collaborative support for G207 development.
  • UAB MedicinecoreStrategic or Co-development PartnerUAB (University of Alabama at Birmingham) Medicine is a key research partner. Co-directed the Neuro Oncology Program and Brain Tumor SPORE in the UAB O'Neal Comprehensive Cancer Center. Founder Yancey Gillespie is Professor Emeritus of Neurosurgery at UAB.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Treovir competitors and assessment

Company assessment

Direct peers

  • Replimune: Replimune is a clinical-stage biotech developing a proprietary platform of engineered oncolytic viruses (RP1, RP2, RP3) across multiple solid tumor indications. It is a direct modality peer with greater pipeline breadth and public-market funding that competes for the same oncolytic virus partnering and clinical site capacity.
  • SillaJen: SillaJen developed Pexa-Vec (JX-594), an oncolytic vaccinia virus, in hepatocellular carcinoma and other solid tumors. It is a clinical-stage direct peer in the oncolytic virus modality with overlapping clinical-trial and regulatory dynamics.
  • Oncorus: Oncorus developed intratumorally and intravenously administered oncolytic HSV-1 immunotherapies for cancer. It is a direct peer in the oncolytic HSV modality that Treovir is built on, with overlapping mechanistic and manufacturing considerations.
  • Genelux: Genelux is developing Olvi-Vec, an oncolytic vaccinia virus, in solid tumors including lung and ovarian cancers. It is a direct modality peer in the clinical-stage oncolytic virus space, competing for investigator attention and partnership capital.
  • Vyriad: Vyriad is developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms for solid tumors. It is a direct peer in clinical-stage oncolytic virus development with similar regulatory and manufacturing challenges to Treovir.
  • DNAtrix: DNAtrix is a clinical-stage oncolytic virus company developing DNX-2401 (tasadenoturev), an oncolytic adenovirus for brain tumors including glioblastoma. It is the most directly comparable peer because it targets the same brain tumor indication with the same oncolytic virus modality as Treovir.
  • Candel Therapeutics: Candel Therapeutics (formerly Advantagene) develops CAN-2409, an oncolytic adenovirus gene therapy, with programs in prostate cancer and high-grade glioma. It directly overlaps Treovir in intratumoral oncolytic virus delivery and brain-tumor indication.

Emerging players

  • Day One Biopharmaceuticals: Day One Biopharmaceuticals is a commercial-stage pediatric oncology company (tovorafenib/Day101) focused exclusively on childhood cancers. It is a peer in the pediatric oncology commercial and clinical-development niche that G207 would enter upon approval.
  • Y-mAbs Therapeutics: Y-mAbs Therapeutics develops and commercializes antibody-based oncology therapies targeted at pediatric tumors, including Danyelza for neuroblastoma. It is comparable as a small, pediatric-cancer-focused biotech operating in the same regulatory and reimbursement environment.

Broad incumbents

  • Amgen (Imlygic / T-Vec): Amgen developed and commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for melanoma. As the established commercial oncolytic virus player, it defines the regulatory and commercial template Treovir would face in bringing G207 to market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Treovir compliance and trust

Trust signal

Compliance3 records

Treovir financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Treovir leadership team

Management profile

Number of profiles

Profiles4 records

Treovir funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Treovir M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treovir

What does Treovir do?

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 (herpes simplex virus type 1) immunotherapy engineered to selectively infect and kill tumor cells while leaving healthy cells unharmed. G207 is administered as a single infusion directly into the brain tumor, causing direct tumor cell death and recruiting the patient's own immune system (T-cell response) to fight the cancer. The company is pursuing FDA approval of G207 for pediatric high-grade glioma, an indication with no currently approved therapies.

Is Treovir a public or private company?

Treovir is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Treovir founded?

Treovir was founded in 2019. It employs 1 to 10 people.

Where is Treovir based?

Treovir is headquartered in Philadelphia, United States, in the North America region.

How does Treovir make money?

One revenue line is on record: pharmaceutical/Biotech Revenue (Future).

Who are Treovir's main competitors?

Direct peers on record are Replimune, SillaJen, Oncorus, Genelux, Vyriad, DNAtrix and Candel Therapeutics. Emerging players are Day One Biopharmaceuticals and Y-mAbs Therapeutics. Amgen (Imlygic / T-Vec) is listed as a broad incumbent.

Does Treovir have an API?

No public API is recorded for Treovir.

What industry is Treovir in?

Treovir's product category is Oncolytic Virus Immunotherapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals